

# Werner Kissling

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12092729/publications.pdf>

Version: 2024-02-01

92  
papers

12,992  
citations

53660

45  
h-index

42291

92  
g-index

108  
all docs

108  
docs citations

108  
times ranked

9513  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. <i>Lancet, The</i> , 2013, 382, 951-962.	6.3	2,094
2	What does the PANSS mean?. <i>Schizophrenia Research</i> , 2005, 79, 231-238.	1.1	1,083
3	Clinical implications of Brief Psychiatric Rating Scale scores. <i>British Journal of Psychiatry</i> , 2005, 187, 366-371.	1.7	799
4	Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. <i>Lancet, The</i> , 2012, 379, 2063-2071.	6.3	742
5	New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. <i>Lancet, The</i> , 2003, 361, 1581-1589.	6.3	667
6	Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2010, 123, 225-233.	1.1	577
7	Amisulpride, an Unusual "Atypical" Antipsychotic: A Meta-Analysis of Randomized Controlled Trials. <i>American Journal of Psychiatry</i> , 2002, 159, 180-190.	4.0	455
8	Relapse Prevention in Schizophrenia With New-Generation Antipsychotics: A Systematic Review and Exploratory Meta-Analysis of Randomized, Controlled Trials. <i>American Journal of Psychiatry</i> , 2003, 160, 1209-1222.	4.0	455
9	Why Olanzapine Beats Risperidone, Risperidone Beats Quetiapine, and Quetiapine Beats Olanzapine: An Exploratory Analysis of Head-to-Head Comparison Studies of Second-Generation Antipsychotics. <i>American Journal of Psychiatry</i> , 2006, 163, 185-194.	4.0	401
10	Oral versus depot antipsychotic drugs for schizophrenia—A critical systematic review and meta-analysis of randomised long-term trials. <i>Schizophrenia Research</i> , 2011, 127, 83-92.	1.1	397
11	Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. <i>British Journal of Psychiatry</i> , 2012, 200, 97-106.	1.7	332
12	Linking the PANSS, BPRS, and CGI: Clinical Implications. <i>Neuropsychopharmacology</i> , 2006, 31, 2318-2325.	2.8	257
13	Efficacy of Pharmacotherapy and Psychotherapy for Adult Psychiatric Disorders. <i>JAMA Psychiatry</i> , 2014, 71, 706.	6.0	244
14	Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons. <i>Schizophrenia Bulletin</i> , 2012, 38, 167-177.	2.3	229
15	Early-Onset Hypothesis of Antipsychotic Drug Action: A Hypothesis Tested, Confirmed and Extended. <i>Biological Psychiatry</i> , 2005, 57, 1543-1549.	0.7	218
16	Do Patients With Schizophrenia Wish to Be Involved in Decisions About Their Medical Treatment?. <i>American Journal of Psychiatry</i> , 2005, 162, 2382-2384.	4.0	203
17	Amitriptyline or Not, That Is the Question: Pharmacogenetic Testing of CYP2D6 and CYP2C19 Identifies Patients with Low or High Risk for Side Effects in Amitriptyline Therapy. <i>Clinical Chemistry</i> , 2005, 51, 376-385.	1.5	162
18	Maintenance treatment with antipsychotic drugs for schizophrenia. <i>The Cochrane Library</i> , 2012, , CD008016.	1.5	154

#	ARTICLE	IF	CITATIONS
19	Shared Decision Making and Long-Term Outcome in Schizophrenia Treatment. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 992-997.	1.1	145
20	Psychiatrists' Use of Shared Decision Making in the Treatment of Schizophrenia: Patient Characteristics and Decision Topics. <i>Psychiatric Services</i> , 2009, 60, 1107-1112.	1.1	135
21	Attitudes of Psychiatrists Toward Antipsychotic Depot Medication. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1948-1953.	1.1	132
22	Participation preferences of patients with acute and chronic conditions. <i>Health Expectations</i> , 2007, 10, 358-363.	1.1	127
23	Allele-Specific Change of Concentration and Functional Gene Dose for the Prediction of Steady-State Serum Concentrations of Amitriptyline and Nortriptyline in CYP2C19 and CYP2D6 Extensive and Intermediate Metabolizers. <i>Clinical Chemistry</i> , 2004, 50, 1623-1633.	1.5	126
24	Quetiapine versus other atypical antipsychotics for schizophrenia. , 2010, , CD006625.		122
25	Olanzapine versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2010, , CD006654.	1.5	120
26	Early Prediction of Antipsychotic Nonresponse Among Patients With Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 352-360.	1.1	118
27	Psychoeducation and Compliance in the Treatment of Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 443-452.	1.1	117
28	Psychoeducation in Schizophrenia--Results of a Survey of All Psychiatric Institutions in Germany, Austria, and Switzerland. <i>Schizophrenia Bulletin</i> , 2005, 32, 765-775.	2.3	105
29	Evidence-based pharmacotherapy of schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2011, 14, 269-284.	1.0	87
30	Trends and perspectives of shared decision-making in schizophrenia and related disorders. <i>Current Opinion in Psychiatry</i> , 2014, 27, 222-229.	3.1	87
31	Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: A systematic review of randomized trials. <i>Schizophrenia Research</i> , 2005, 80, 85-97.	1.1	81
32	Psychoeducation in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 854-861.	1.1	81
33	Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials. <i>Schizophrenia Research</i> , 2004, 70, 33-37.	1.1	73
34	â€œHow to Speak to Your Psychiatristâ€: Shared Decision-Making Training for Inpatients With Schizophrenia. <i>Psychiatric Services</i> , 2011, 62, 1218-1221.	1.1	73
35	Risperidone versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2011, , CD006626.	1.5	69
36	Psychoeducation in schizophrenia: new developments and approaches in the field. <i>Current Opinion in Psychiatry</i> , 2008, 21, 168-172.	3.1	66

#	ARTICLE	IF	CITATIONS
37	Aripiprazole versus other atypical antipsychotics for schizophrenia. , 2009, , CD006569.		57
38	Lithium for schizophrenia. The Cochrane Library, 2015, 2015, CD003834.	1.5	57
39	Predicting antipsychotic drug response – Replication and extension to six weeks in an international olanzapine study. Schizophrenia Research, 2008, 101, 312-319.	1.1	56
40	Maintenance treatment with antipsychotic drugs for schizophrenia. The Cochrane Library, 2020, 2020, CD008016.	1.5	56
41	Patients'™ and Psychiatrists'™ Perceptions of Clinical Decisions During Schizophrenia Treatment. Journal of Nervous and Mental Disease, 2008, 196, 329-332.	0.5	55
42	Lithium for Schizophrenia Revisited. Journal of Clinical Psychiatry, 2004, 65, 177-186.	1.1	55
43	Second-generation antipsychotics for anxiety disorders. The Cochrane Library, 2010, , CD008120.	1.5	54
44	Second-generation antipsychotics for obsessive compulsive disorder. The Cochrane Library, 2010, , CD008141.	1.5	54
45	Peer-to-Peer Psychoeducation in Schizophrenia. Journal of Clinical Psychiatry, 2005, 66, 1580-1585.	1.1	53
46	Partial Compliance With Antipsychotic Medication is Common in Patients With Schizophrenia. Australian and New Zealand Journal of Psychiatry, 2008, 42, 382-388.	1.3	51
47	Medical Decision Making in Antipsychotic Drug Choice for Schizophrenia. American Journal of Psychiatry, 2004, 161, 1301-1304.	4.0	50
48	Do physicians'™ recommendations pull patients away from their preferred treatment options?. Health Expectations, 2012, 15, 23-31.	1.1	47
49	How should patients behave to facilitate shared decision making – the doctors'™ view. Health Expectations, 2012, 15, 360-366.	1.1	47
50	On the concept of remission in schizophrenia. Psychopharmacology, 2007, 194, 453-461.	1.5	46
51	Ziprasidone versus other atypical antipsychotics for schizophrenia. The Cochrane Library, 2009, , CD006627.	1.5	45
52	Psychoeducation for patients with schizophrenia and their families. Expert Review of Neurotherapeutics, 2008, 8, 1067-1077.	1.4	43
53	Amisulpride is an 'atypical' antipsychotic associated with low weight gain. Psychopharmacology, 2004, 173, 112-115.	1.5	42
54	Carbamazepine Augmentation for Schizophrenia. Journal of Clinical Psychiatry, 2002, 63, 218-224.	1.1	38

#	ARTICLE	IF	CITATIONS
55	Comparative remission rates of schizophrenic patients using various remission criteria. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1643-1651.	2.5	37
56	Effects of a question prompt sheet on active patient behaviour: A randomized controlled trial with depressed outpatients. International Journal of Social Psychiatry, 2014, 60, 227-235.	1.6	32
57	Identifying the profile of optimal candidates for antipsychotic depot therapy. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1987-1993.	2.5	31
58	Patient participation in antipsychotic drug choice decisions. Psychiatry Research, 2010, 178, 63-67.	1.7	31
59	Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. The Cochrane Library, 2014, 2014, CD009268.	1.5	31
60	Training patients with schizophrenia to share decisions with their psychiatrists: a randomized-controlled trial. Social Psychiatry and Psychiatric Epidemiology, 2017, 52, 175-182.	1.6	28
61	Amisulpride versus other atypical antipsychotics for schizophrenia. The Cochrane Library, 2010, , CD006624.	1.5	26
62	How much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed?. European Neuropsychopharmacology, 2010, 20, 276-279.	0.3	26
63	Equipercntile linking of the Brief Psychiatric Rating Scale and the Clinical Global Impression Scale in a catchment area. European Neuropsychopharmacology, 2012, 22, 501-505.	0.3	26
64	Carbamazepine for schizophrenia. The Cochrane Library, 2014, , CD001258.	1.5	26
65	Psychoeducation Improves Compliance and Outcome in Schizophrenia Without an Increase of Adverse Side Effects: A 7-Year Follow-up of the Munich PIP-Study. Schizophrenia Bulletin, 2016, 42, S62-S70.	2.3	26
66	How do patients from eastern and western Germany compare with regard to their preferences for shared decision making?. European Journal of Public Health, 2012, 22, 469-473.	0.1	25
67	Frequency and relevance of psychoeducation in psychiatric diagnoses: Results of two surveys five years apart in German-speaking European countries. BMC Psychiatry, 2013, 13, 170.	1.1	24
68	Using films as a psychoeducation tool for patients with schizophrenia: a pilot study using a quasi-experimental pre-post design. BMC Psychiatry, 2015, 15, 93.	1.1	24
69	Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1012-1022.	2.5	23
70	Peer-counseling in schizophrenia: Patients consult patients. Patient Education and Counseling, 2008, 70, 357-362.	1.0	20
71	Can Psychiatrists and Neurologists Predict Their Patients' Participation Preferences?. Journal of Nervous and Mental Disease, 2010, 198, 309-311.	0.5	18
72	Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia. Schizophrenia Research and Treatment, 2012, 2012, 1-3.	0.7	18

#	ARTICLE	IF	CITATIONS
73	Checking the plausibility of psychiatrists' arguments for not prescribing depot medication. <i>European Neuropsychopharmacology</i> , 2014, 24, 1506-1510.	0.3	18
74	Psychoeducation in anxiety disorders: Results of a survey of all psychiatric institutions in Germany, Austria and Switzerland. <i>Psychiatry Research</i> , 2009, 169, 180-182.	1.7	17
75	Long-term observation of patients successfully switched to risperidone long-acting injectable: A retrospective, naturalistic 18-month mirror-image study of hospitalization rates and therapy costs. <i>International Journal of Psychiatry in Clinical Practice</i> , 2010, 14, 53-62.	1.2	17
76	A Fast, Implementable Psychoeducation Program for Schizophrenia. <i>Psychiatric Services</i> , 2007, 58, 1226-1226.	1.1	16
77	How do psychiatrists choose among different antipsychotics?. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 851-854.	0.8	14
78	Psychiatric Decision Making in the Adoption of a New Antipsychotic in Germany. <i>Psychiatric Services</i> , 2006, 57, 700-703.	1.1	14
79	Sertindole versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2009, , CD006752.	1.5	13
80	Maintenance Treatment With Antipsychotic Drugs in Schizophrenia: A Cochrane Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , 2022, 48, 738-740.	2.3	13
81	Zotepine versus other atypical antipsychotics for schizophrenia. , 2010, , CD006628.		10
82	Psychiatrist and Patient Responses to Suspected Medication Nonadherence in Schizophrenia Spectrum Disorders. <i>Psychiatric Services</i> , 2014, 65, 881-887.	1.1	9
83	Effects of an integrated care program for outpatients with affective or psychotic disorders. <i>Psychiatry Research</i> , 2014, 217, 15-19.	1.7	8
84	Zotepine versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2010, , CD006628.	1.5	7
85	Patients' acceptance of the deltoid application of risperidone long-acting injection. <i>European Neuropsychopharmacology</i> , 2012, 22, 897-901.	0.3	7
86	Does it matter whether physicians' recommendations are given early or late in the decision-making process? An experimental study among patients with schizophrenia. <i>BMJ Open</i> , 2016, 6, e011282.	0.8	7
87	Caregiver psychoeducation for schizophrenia: Is gender important? " Comments on the study by McWilliams et al., 2007. <i>European Psychiatry</i> , 2007, 22, 479-480.	0.1	6
88	Psychoeducation in dementia: Results of a survey of all psychiatric institutions in Germany, Austria and Switzerland. <i>Psychiatry and Clinical Neurosciences</i> , 2008, 62, 751-751.	1.0	4
89	Are new drugs for schizophrenia better than old ones? " Authors' reply. <i>Lancet, The</i> , 2009, 373, 1249-1250.	6.3	4
90	Evidence-based pharmacotherapy of schizophrenia. , 0, , 18-38.		1

#	ARTICLE	IF	CITATIONS
91	Comparative Efficacy and Tolerability of 15 Antipsychotic Drugs in Schizophrenia: A Multiple-Treatments Meta-Analysis. Focus (American Psychiatric Publishing), 2014, 12, 192-204.	0.4	1
92	Dr. Hamann and Colleagues Reply. American Journal of Psychiatry, 2006, 163, 937-937.	4.0	0